ストックスクリーナーアプリを入手
0.9486
8.51%
-0.0814
前日終値:
$1.03
開ける：
$1.01
24時間の取引高:
919.64K
Relative Volume:
0.81
時価総額：
$267.00M
収益：
$54,000
当期純損益:
$-210.26M
株価収益率:
-1.1293
EPS:
-0.84
ネットキャッシュフロー:
$-159.01M
1週間 パフォーマンス:
-14.34%
1か月 パフォーマンス:
-15.87%
6か月 パフォーマンス:
-63.90%
1年 パフォーマンス:
-46.61%
1日の値動き範囲:
$0.9359
$1.04
1週間の範囲:
$0.8638
$1.16
52週間の値動き範囲:
$0.85
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
名前
Lyell Immunopharma Inc
セクター
電話
650 695-0677
住所
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LYEL | 0.9475 | 267.00M | 54,000 | -210.26M | -159.01M | -0.84 |
| VRTX | 450.27 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.65 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.61 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.57 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | ダウングレード | Goldman | Buy → Neutral |
| 2022-10-17 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | BofA Securities | Buy |
| 2021-07-12 | 開始されました | Goldman | Buy |
| 2021-07-12 | 開始されました | JP Morgan | Overweight |
| 2021-07-12 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Lyell Immunopharma Inc (LYEL) 最新ニュース
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reiterates "Neutral" Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
The Analyst Verdict: Lyell Immunopharma In The Eyes Of 4 Experts - Benzinga
Lyell Immunopharma: Q3 Earnings Snapshot - AOL
Lyell Immunopharma Reports Q3 2024 Financial Results - TipRanks
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024 - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from - GlobeNewswire
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Lyell's Novel CAR T-Cell Therapy Data to Be Unveiled at ASH 2024 Following FDA Fast Track Status | LYEL Stock News - StockTitan
Vanguard Group Inc's Strategic Reduction in Lyell Immunopharma I - GuruFocus.com
Lyell shares down as BofA double downgrades to Sell - MSN
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to “Underperform” Rating by Bank of America - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio South San Francisco, Calif., Oct. 31, 2024 – Lyell Immunopharma, Inc. (NASDAQ: LYEL), a clinical-stage T-cell reprogramming company focusing on next-generation CAR T-cell therapies for solid - Defense World
Lyell Immunopharma Completes Acquisition of ImmPACT Bio - The Manila Times
Lyell Immunopharma acquires ImmPACT Bio to boost CAR T-cell therapy - Investing.com India
B of A Securities Downgrades Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma’s (LYEL) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Lyell shares down as BofA double downgrades to Sell By Investing.com - Investing.com Australia
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy - Benzinga
Lyell cut to underperform by BofA, pipeline reorganization cited - MSN
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Underperform Rating by Bank of America - MarketBeat
HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
Lyell Immunopharma shares maintain neutral rating on acquisition By Investing.com - Investing.com UK
Lyell Immunopharma’s Acquistion of ImmPACT Bio USA - Global Legal Chronicle
Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT - Citeline News & Insights
Lyell Immunopharma stock hits 52-week low at $1.05 By Investing.com - Investing.com Australia
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline - Pharmaceutical Technology
Lyell Immunopharma stock hits 52-week low at $1.05 - Investing.com
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition - Investing.com India
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact - BioPharma Dive
Lyell Immunopharma to Buy ImmPact; Refocuses Pipeline on T-Cell Cancer Treatments - MarketWatch
Lyell Immunopharma to acquire ImmPACT Bio (NASDAQ:LYEL) - Seeking Alpha
Lyell boosts pipeline with ImmPACT acquisition By Investing.com - Investing.com South Africa
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes - GlobeNewswire
Lyell Immunopharma Inc (LYEL) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):